KRAS mutation profile differences between rectosigmoid localized adenocarcinomas and colon adenocarcinomas

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Colorectal cancer (CRC) exhibits significant heterogeneity influenced by tumor site.
• While colon and rectal cancer genetic alterations are studied, KRAS mutations in rectosigmoid vs. colon cancers remain under-characterized.
• Understanding KRAS mutational differences is crucial for targeted therapies.

Purpose of the Study:

• To investigate and compare the frequency of KRAS gene mutations between rectosigmoid and colon cancers.
• To assess the correlation between KRAS mutation status and tumor location in colorectal cancer.

Main Methods:

• Genomic DNA extraction from 84 formalin-fixed paraffin-embedded colorectal cancer tissues.
• KRAS mutation analysis targeting seven common mutations (Gly12Ala, Gly12Asp, Gly12Arg, Gly12Cys, Gly12Ser, Gly12Val, and Gly13Asp).
• Statistical analysis using the Chi-square test to evaluate associations.

Main Results:

• This study provides the first KRAS mutation data for Turkish rectosigmoid cancer patients.
• KRAS mutation frequency was 34.3% in rectosigmoid tumors versus 30.6% in colon tumors.
• No statistically significant correlation was found between KRAS mutation status and tumor location (rectosigmoid vs. colon).

Conclusions:

• KRAS mutation analysis offers predictive and prognostic value, identifying potential treatment resistance.
• Biological behavior differences between rectosigmoid and colon cancers warrant consideration.
• Cancer genotyping aids personalized management strategies for colorectal cancer patients.